Featured Article

Cephalon Settles in Drug Marketing Investigation
Article Audio

1:09 minutes (0.56 MB)
Download this Article
Share this Content

A pharmaceutical company  will pay Connecticut more than six million dollars to resolve an investigation into whether it marketed drugs beyond their approved use.

Attorney General Richard Blumenthal announced the more than $6 million settlement with Cephalon. He says it covers the marketing of three drugs: Actiq, Gabitril, and Provigil.  

"It really very purposefully, concertedly, consciously marketed these products to a much broader array of physicians than were approved to treat the kind of diseases that it was supposed to provide relief for."

More than half of the $6 million settlement will fund cancer programs through the Connecticut Department of Public Health. Another $2.1 million will pay restitution to state agencies and programs.

The investigation followed the 2003 death of a 20 year-old woman who overdosed on the painkiller Actiq at a Southington party.

The attorney general's office says such illegal use became more likely as the drug became increasingly available.

Pennsylvania-based Cephalon is also settling a federal Medicaid fraud investigation for $425 million.

The company did not admit any wrongdoing in the state settlement, though it did plead guilty to a federal misdemeanor for marketing the three drugs beyond their approved use.